Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
Axsome Therapeutics reported Q2 2026 earnings that met EPS estimates but missed revenue expectations at $218.4M vs. $225M consensus. While lead drug Auvelity drove strong 51% YoY sales growth to $180.3M and Sunosi performed well, newest drug Symbravo significantly underperformed at $2.3M against $7.2M estimates. Post-earnings, analyst estimates have trended downward, and the stock has underperformed the S&P 500 by 3.7% over the past month.